The Financial Express22h
AstraZeneca’s Fasenra set to revolutionise COPD treatment as Phase III data builds anticipation
AstraZeneca’s respiratory and immunology portfolio is driving significant growth, with R&I assets forecasted to account for ...
The Pharma Letter2d
AstraZeneca's Fasenra set to revolutionize COPD treatment
UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...
What are the symptoms of emphysema?
Emphysema is a chronic lung condition that affects millions of people worldwide and can make everyday activities such as ...
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth
AstraZeneca’s Fasenra, an IL-5-targeting monoclonal antibody already approved for asthma, represents a promising contender ...
emjreviews.com5d
Home High-Flow Therapy Offers Promise for COPD Recovery
Study finds home high-flow therapy may enhance COPD recovery after severe exacerbations, improving symptoms and reducing ...
pulmonologyadvisor6d
In Asthma, Lower End-Tidal Carbon Dioxide May Predict Worse Exacerbation Outcome
In asthma, lower end-tidal carbon dioxide may predict acute exacerbation outcomes, although other measures may be better severity indicators.
Too Old to Operate6d
Benralizumab Improves Outcomes in Acute Eosinophilic Exacerbations
The following is a summary of “Treating eosinophilic exacerbations of asthma and COPD with benralizumab (ABRA): a ...
Too Old to Operate6d
Tezepelumab Failed to Meet Primary Endpoint in COPD Study
The following is a summary of “Efficacy and safety of tezepelumab versus placebo in adults with moderate to very severe ...